UK biotech sees boost in biotech fundrais­ing so far this year; Chemo­Cen­tryx kills plans for stock of­fer

→ BIA and In­for­ma Phar­ma In­tel­li­gence re­port­ed Fri­day that the UK biotech in­dus­try saw $2.05 bil­lion in new fundrais­ing in the first 8 months of this year — more than all of last year. That fig­ure adds ven­ture rounds with IPOs and fol­low-ons. 

→ Chemo­Cen­tryx $CCXI is can­celling plans for a new of­fer­ing to raise cash. The Moun­tain View, CA-based biotech says that “the com­pa­ny be­lieves that cul­mi­na­tion of terms rep­re­sent­ing the best in­ter­ests of its stock­hold­ers is not to be achieved at the cur­rent time.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER